A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures
The X-TOLE2 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study
that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as
adjunctive therapy in focal-onset seizures.
Age: 18 years - 66+
Gender: All
RNS System LGS Feasibility Study
To generate preliminary safety and effectiveness data for brain-responsive neurostimulation
of thalamocortical networks as an adjunctive therapy in reducing the frequency of generalized
seizures in individuals 12 years of age or older with Lennox Gastaut Syndrome (L...
Age: 12 years - 66+
Gender: All
The Efficacy of a Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy
Ketamine is a medication that came into clinical practice in the 1960's. Ketamine is used as
an anesthetic and to provide pain relief. Recently, Ketamine was approved to treat drug
resistant depression using subanesthetic doses. In the hospital setting, intravenous
...
Age: 18 years - 66+
Gender: All
RNS System RESPONSE Study
To demonstrate that the RNS System is safe and effective as an adjunctive therapy in
individuals age 12 through 17 years with medically refractory partial onset epilepsy.
Age: 12 - 17 years
Gender: All